Impacts of perianal disease and faecal incontinence on quality of life and employment in 1092 patients with inflammatory bowel disease by Vollebregt, PF et al.
Impacts of perianal disease and faecal incontinence on quality
of life and employment in 1092 patients with inflammatory
bowel disease
P. F. Vollebregt1 | A. A. van Bodegraven1,2 | T. M. L. Markus-de Kwaadsteniet3 |
D. van der Horst3 | R. J. F. Felt-Bersma1
1Department of Gastroenterology and
Hepatology, VU University Medical Centre,
Amsterdam, The Netherlands
2Department of Gastroenterology,
Geriatrics, Internal Medicine and Intensive
Care Medicine (Co-MIK), Zuyderland
Medical Centre, Heerlen-Geleen-Sittard,
The Netherlands
3Dutch Crohn’s and Colitis organisation
(CCUVN), Woerden, The Netherlands
Correspondence
Dr. P. F. Vollebregt, Department of
Gastroenterology and Hepatology, VU
University Medical Centre, Amsterdam, The
Netherlands.
Email: p.vollebregt@vumc.nl
Summary
Background: Patient reported outcomes regarding perianal disease and faecal incontinence
in the community-based inflammatory bowel disease population are poorly described.
Aims: To determine the impacts of perianal disease and faecal incontinence on quality of
life and employment in inflammatory bowel disease patients.
Methods: For this cross-sectional study, a comprehensive survey was sent out to mem-
bers of the Dutch National Crohn’s and Colitis patient organisation. Validated question-
naires regarding faecal incontinence and active perianal disease were used to estimate its
prevalence’s. The effect on the quality of life (36-Item Short Form Survey) and on employ-
ment status (multivariate binary regression analysis) was assessed in this inflammatory
bowel disease population.
Results: A total number of 1092 returned questionnaires (58% responders) were used for
analysis; 750 respondents (69%) were female; mean age was 47 years (IQR 35-59). In 621
patients (57%) Crohn’s disease, in 422 (39%) ulcerative colitis and in 49 (4%) patients unclassi-
fiable inflammatory bowel disease was self-reported. The 114 patients (10%) with a stoma
were excluded for continence related analyses. Faecal incontinence was reported in 555
patients (57%), was comparable between the different inflammatory bowel disease diagnoses
and affected all 36-Item Short Form Survey subscales adversely (incontinence vs continence:
Physical functioning 75 vs 84, P < 0.0001; Limitations due to physical health 49 vs 63,
P < 0.0001; Limitations due to emotional problems 49 vs 64, P < 0.0001; Energy/fatigue 47
vs 53, P < 0.0001; Emotional well-being 71 vs 74, P = 0.005; Social functioning 63 vs 73,
P < 0.0001; Pain 66 vs 75, P < 0.0001; General health 41 vs 48, P < 0.0001). Active perianal
disease was reported in 39% Crohn’s disease, 16% ulcerative colitis (84% fissures) and 20%
unclassifiable inflammatory bowel disease patients. Faecal incontinence was more common in
patients with perianal disease (67% vs 53%, P = 0.003). When correcting for age, disease
duration, inflammatory bowel disease-related surgery and faecal incontinence, active perianal
disease was independently affecting employment (OR 0.67; 95% CI 0.50–0.91; P = 0.01).
Conclusions: Faecal incontinence and perianal disease are quality of life determining fac-
tors. Faecal incontinence needs more attention among clinicians, and development of new
(drug) therapies needs to be focussed on perianal disease.
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1 | INTRODUCTION
Inflammatory bowel disease (IBD) mainly comprises Crohn’s disease
(CD) and ulcerative colitis (UC). It is well known that these rela-
tively common conditions consume significant healthcare
resources,1,2 and may compromise patient’s quality of life.3 As the
diseases are chronic, symptoms of most concern to the patients
have to be characterised and treatment needs to be guided by
quality of life above all else. However, a large proportion of
patients is not able to express potentially important information to
their physician with regard to their complaints,3 and almost 50%
report that their physician does not ask about the impact of their
symptoms on quality of life.4 Awareness amongst clinicians is
needed regarding complaints causing the highest burden in this
population, to prioritise treatment and development of new thera-
peutic strategies.
Faecal incontinence, usually defined as the uncontrolled loss or
liquid of solid stool, is one of the concerns reported by IBD-
patients.5 Its prevalence amongst the IBD-population, which has
only been investigated in five studies to date, is estimated between
20% and 38% in tertiary centers6–9 and even up to 74% in a com-
munity-based population.10 The latter has only been reported once,
precluding reliable data on community-based prevalence numbers
of faecal incontinence and its association with quality of life. In a
cross-sectional study, only 3% of patients had a medical diagnosis
of faecal incontinence, whilst 36% reported complaints.11 Indis-
putably, the anal function warrants (medical) attention and physi-
cians (gastroenterologist and colorectal surgeons, in particular) need
to ask actively.
Perianal disease (ie, fissures, fistulas, abscesses and stenosis)
occurs in a considerable group of patients with CD, and is associated
with a more extensive and complicated disease behaviour.12 The
prevalence of these, usually embarrassing, complaints is reported in
a wide range, partly due to a variety of used definitions.13 The lim-
ited number of studies addressing this have mainly focussed on ter-
tiary populations,14 hence a community-based, more accurate
estimation has barely been reported.15,16 If documented, anal pain
and discomfort seem unfavourable factors compromising quality of
life,17 and self-reported depressive symptoms are frequently con-
comitantly observed,18 underlining the negative impact on quality of
life.
In this cross-sectional study, we aimed to survey the prevalence
of faecal incontinence and perianal disease, and related its occur-
rence with perceived quality of life, in a large population-based
cohort of members of the Dutch Crohn’s and Colitis patients’
organisation (CCUVN).
2 | METHODS
2.1 | Study population
In October 2016, CCUVN had a total membership database of
10 047 patients. A comprehensive, anonymised study questionnaire
(Data S1) was sent out online (via a purpose-designed secure web-
site) by the CCUVN in January 2015 and October 2016 to a panel
which consisted of 1710 CCUVN patients (1206 female) in October
2016. The panel is represented by patients who gave consent to
participate in online surveys with regard to disease-related subjects,
which are carried out several times a year. A reminder was sent out
to nonresponders after 3 weeks. In addition, a link to the question-
naire was added to the monthly CCUVN newsletter of January
2015. Inclusion criteria were age over 18 years old and a self-
reported diagnosis of IBD.
2.2 | Questionnaires
The close-ended survey included a self-reported IBD diagnosis (CD,
UC or ‘IBD-U’ if the type of disease was not classifiable by the
patient, or if UC was reported with the presence of small bowel dis-
ease), perianal disease activity index,19 St. Marks incontinence
score,20 36-Item Short Form Survey21 and the faecal incontinence
quality of life questionnaire.22 Faecal incontinence was defined as
the involuntary loss of liquid or solid stool at least once per month.
Active perianal disease was described as a score of ≥1 for the cate-
gory “Type of perianal disease” on the perianal disease activity index.
An additional questionnaire was developed to collect data with
regard to basic and disease characteristics, and previously performed
(IBD-related) surgical interventions.
2.3 | Statistical analysis
Patients with CD, UC and IBD-U were characterised by the use of
descriptive statistics. Continuous variables were described as means
with interquartile ranges (IQR), categorical variables as percentages.
Differences between continuous variables were studied with the use
of the Student’s t test and chi-square was used for categorical vari-
ables. One-way ANOVA was used for comparison of continuous
variables between >2 groups. All patients had complete data for the
basic characteristics (age, sex, type of disease [CD, UC, IBD-U], dis-
ease localisation and stoma surgery). For variables with missing data,
multiple imputation was performed using the Markov Chain Monte
Carlo method (total variables missing 2.4%; job description 0.1%;
operational procedures 0.6%; age at diagnosis 1.7%; influence of
IBD on job description 2.4%; 36-Item Short Form Survey 2.5%;
effect of IBD on productivity at work during the past 6 months
3.4%; sick leave during the past 6 months because of IBD 3.6%; St.
Marks incontinence score 4.7%; perianal disease activity index 5.8%;
faecal incontinence quality of life questionnaire 7.1%). As a total of
52% of patients had a complete dataset, multiple imputations are
appropriate technique or imputation of missing data.23 Little’s MCAR
test was performed for determining whether missing values were
missing completely at random.24 Ten imputed data sets were created
and pooled. Patients with a stoma were excluded in continence-
related analyses. Basic and disease characteristics which were associ-
ated with employment status (P < 0.10) were included in the multi-
variable logistic regression model to identify independent associated
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factors (P < 0.05 considered statistical significant), with results pre-
sented as effect sizes (Odds Ratio) with 95% CI. Statistical analysis
was performed using SPSS Statistics version 21 (IBM Corp, Armonk,
NY, USA).
2.4 | Ethical statement
This study was initiated by the CCUVN. The members of the
selected panel gave consent to participate in anonymous health-
related surveys.
3 | RESULTS
3.1 | Patient population
A total of 1120 patients responded to the questionnaire. Of these
patients, 997 (91%) were member of the CCUVN panel, resulting in
a response rate of 58%. The other 95 (9%) responded the question-
naire via the CCUVN newsletter. Twenty-eight patients were
excluded due to the age of <18 years (n = 14), lack of information
regarding their diagnosis (n = 11), and missing basic characteristics
(n = 3). The remaining 1092 patients were slightly younger (47 vs
48 years; P = 0.02) compared to the 9100 CCUVN patients (91%)
who registered their age and gender; there was no difference in gen-
der (69% vs 66% females; P = 0.06). Demographics, disease charac-
teristics and previously performed IBD-related surgery of the 1092
patients are shown in Table 1 (CD = 621; UC = 422; IBD-U = 49).
Overall, 376 female patients (50%) had at least one vaginal delivery.
CD patients were younger than UC patients (46 vs 49 years;
P = 0.001). They were diagnosed with CD at a younger age than UC
patients (32 vs 38 years; P < 0.0001), and had a longer disease dura-
tion compared to IBD-U patients (14 vs 9 years; P = 0.011). CD
patients underwent more often IBD-related abdominal surgery (CD
44%, UC 10% and IBD-U 12%; P < 0.0001). Active perianal disease
was reported by 244 CD patients (39%), 69 UC patients (16%) and
10 IBD-U patients (20%). Of these, a total of 58 UC patients (84%)
reported anal fissures only. Perianal surgery was predominantly per-
formed in CD patients (fistula surgery 19%; abscess surgery 20%),
although also reported amongst the UC population (fistula surgery
2%; abscess surgery 3%).
3.2 | Faecal incontinence
To describe the prevalence of faecal incontinence, all patients with
a stoma were excluded (CD = 92, UC = 19, IBD-U = 3). Faecal
incontinence was reported in 555 patients (57%) (306 CD patients
[58%], 225 UC patients [56%] and 24 IBD-U patients [52%],
Table 2). The mean St. Marks incontinence score was higher in
CD patients compared to IBD-U patients (9 vs 7; P = 0.011). Fae-
cal incontinence was frequently associated with a flare-up in all
types of diagnoses (CD 42%; UC 56%; IBD-U 42%), more often in
UC compared to CD patients (P = 0.005). Furthermore, a total of
125 CD (41%), 78 UC (35%) and 9 IBD-U patients (38%) reported
faecal incontinence episodes during periods of remission in addi-
tion. Twenty-three per cent of CD patients who underwent peri-
anal surgery reported that symptoms of faecal incontinence were
related to the perianal surgery. Quality of life on all of the four
faecal incontinence quality of life subscales (ranging 0-4) was
affected, regardless the type of diagnosis. As shown in Table 3,
incontinent patients reported a lower 36-Item Short Form Survey
score on all different subscales compared to continent patients
(Physical functioning 75 vs 84, P < 0.0001; Limitations due to
physical health 49 vs 63, P < 0.0001; Limitations due to emotional
problems 49 vs 64, P < 0.0001; Energy/fatigue 47 vs 53,
P < 0.0001; Emotional well-being 71 vs 74, P = 0.005; Social func-
tioning 63 vs 73, P < 0.0001; Pain 66 vs 75, P < 0.0001; General
health 41 vs 48, P < 0.0001). Patients with an age over 65 were
excluded to assess the impact of faecal incontinence on daily
work. Less incontinent patients reported a paid job (65% vs 74%;
P = 0.002).
3.3 | Perianal disease
Patients from all diagnoses (CD, UC and IBD-U) with perianal disease
(n = 323) were compared to IBD patients without perianal disease
(n = 769) with regard to their quality of life, employment and the
association with faecal incontinence (Table 4). Patients with perianal
disease reported a lower 36-Item Short Form Survey score on all dif-
ferent subscales (Physical functioning 74 vs 80, P < 0.0001; Limita-
tions due to physical health 47 vs 57, P = 0.001; Limitations due to
emotional problems 47 vs 57, P = 0.0002; Energy/fatigue 44 vs 52,
P < 0.0001; Emotional well-being 69 vs 73, P = 0.001; Social func-
tioning 60 vs 69, P < 0.0001; Pain 62 vs 72, P < 0.0001; General
health 39 vs 45, P < 0.0001). Restriction of sexual activities was
reported amongst more than two-third of the patients with perianal
disease (no restriction 31%; slight restriction 28%; moderate limita-
tions 25%; marked limitations 12%; unable to engage in sexual
activities 4%).
Patients with an age over 65 were excluded to assess the
impact of perianal disease on daily work. Less patients with peri-
anal disease reported a paid job (61% vs 69%; P = 0.004), and a
higher proportion of patients with perianal disease reported that
their job type was a result of their IBD (34% vs 21%; P < 0.0001).
Patients with perianal disease were more likely to report sick leave
during the past 6 months (48% vs 36%; P = 0.007), and the effect
of their IBD on their work productivity during the past 6 months
was reported to be higher on a 0-10 Likert scale (4.6 vs 3.9;
P = 0.01).
Subsequently, patients with a stoma were excluded to analyse
the prevalence and impact of faecal incontinence on quality of life in
IBD patients with perianal disease compared to other IBD patients.
Faecal incontinence was more commonly reported amongst patients
with perianal disease compared to patients without perianal disease
(67% vs 53%; P = 0.003). In addition, incontinent patients with peri-
anal disease reported a lower quality of life on all of the four differ-
ent faecal incontinence quality of life subscales.
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3.4 | Employment status—binary regression
analysis
As faecal incontinence was more commonly reported amongst
patients with perianal disease, a multivariate binary regression anal-
ysis was performed to investigate the independent impact of both
complaints on employment status. The results in Table 5 show that
perianal disease (Odds Ratio 0.71; 95% CI 0.53-0.95; P = 0.02) and
faecal incontinence (Odds ratio 0.68; 95% CI 0.51-0.90; P = 0.007)
are both independently affecting employment status (no paid
job = 0 vs paid job = 1), when corrected for the presence of a
stoma. Table S1 shows a univariate analysis of all basic characteris-
tics and other factors with a possible effect on employment status.
Age (Odds ratio 0.95; 95% CI 0.94-0.96; P < 0.0001), age at diag-
nosis (Odds ratio 0.98; 95% CI 0.97-0.99; P < 0.0001), disease
duration (Odds ratio 0.96; 95% CI 0.95-0.97; P < 0.0001), subtotal
colectomy (Odds ratio 0.31; 95% CI 0.16-0.57; P = 0.0002), Ileal
pouch-anal anastomosis (Odds ratio 0.47; 95% CI 0.20-1.12;
P = 0.09), abdominal abscess surgery (Odds ratio 0.53; 95% CI
0.30-0.92; P = 0.02), stoma (Odds ratio 0.63; 95% CI 0.41-0.95;
P = 0.03), active perianal disease (Odds ratio 0.66; 95% CI 0.50-
0.88; P = 0.004), perianal surgery (Odds ratio 0.63; 95% CI 0.45-
0.90; P = 0.01) and faecal incontinence (Odds ratio 0.65; 95% CI
0.49-0.86; P = 0.002) were all affecting employment status.
Disease duration and age at diagnosis (P < 0.0001), and active
perianal disease and perianal surgery (P < 0.0001) were highly corre-
lated variables, therefore age at diagnosis and perianal surgery were
not added to the final model. In the multivariate model (Table S1),
age (Odds ratio 0.96; 95% CI 0.94-0.97; P < 0.0001), subtotal colec-
tomy (Odds ratio 0.37; 95% CI 0.17-0.80; P = 0.01) and active peri-
anal disease (Odds ratio 0.67; 95% CI 0.49-0.91; P = 0.01) were
independently affecting employment status. Faecal incontinence lost
its effect in this model (P = 0.15) due to the addition of age, as
incontinent patients were older compared to continent patients (47
vs 42 years; P < 0.0001).
TABLE 1 Demographics, disease characteristics and previously
performed IBD-related surgery of the total group (n = 1092)
Variable
Crohn’s
disease
Ulcerative
colitis
IBD not
classifiable
by patient
Number of
patients
621 (57%) 422 (39%) 49 (4%)
Gender
Female 459 (74%) 262 (62%) 29 (59%)
Vaginal
delivery
214 (47%) 145 (55%) 17 (59%)
1 71 (33%) 44 (30%) 8 (47%)
2 104 (49%) 84 (58%) 6 (35%)
3 29 (14%) 12 (8%) 0
4 9 (4%) 3 (2%) 3 (18%)
>4 1 (0.5%) 2 (2%) 0
Male 162 (26%) 160 (38%) 20 (41%)
Age—yearsa
(mean, IQR)
46 (34-57) 49 (37-61) 46 (35-57)
Age at
diagnosis—yearsb
(mean, IQR)
32 (30-41) 38 (26-48) 37 (29-46)
Disease
duration—yearsc
(mean, IQR)
14 (10-19) 12 (3-19) 9 (2-13)
Disease location
Oesophagus/
stomach
44 (7%) 0 3 (6%)
Small bowel 173 (28%) 0 6 (12%)
Large bowel 181 (29%) 357 (85%) 30 (61%)
Rectum 142 (23%) 65 (15%) 16 (33%)
Small and large
bowel
244 (39%) 0 9 (18%)
IBD-related
abdominal surgeryd
272 (44%) 40 (10%) 6 (12%)
Bowel resection 219 (35%) 8 (2%) 3 (6%)
Subtotal
colectomy
31 (5%) 18 (4%) 2 (4%)
Ileal pouch-anal
anastomosis
11 (2%) 11 (3%) 1 (2%)
Abscess 56 (9%) 3 (0.7%) 0
Stoma 92 (15%) 19 (5%) 3 (6%)
Active perianal disease
No 377 (61%) 353 (84%) 39 (80%)
Yes 244 (39%) 69 (16%) 10 (20%)
Perianal surgery
Fistula
Surgery 121 (19%) 8 (2%) 2 (4%)
Seton 61 (10%) 1 (0.2%) 0
(Continues)
TABLE 1 (Continued)
Variable
Crohn’s
disease
Ulcerative
colitis
IBD not
classifiable
by patient
Abscess
Surgery 124 (20%) 11 (3%) 0
aCrohn’s disease patients younger than ulcerative colitis patients
(P = 0.001).
bCrohn’s disease patients diagnosed at younger age than ulcerative colitis
patients (P < 0.0001).
cCrohn’s disease patients longer disease duration than not classifiable
IBD-patients patients (P = 0.011).
dCrohn’s disease patients underwent more frequently abdominal surgery
than ulcerative colitis patients (P < 0.0001) and not-classifiable IBD-
patients (P < 0.0001).
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4 | DISCUSSION
In this community-based IBD population, we observed that more
than half of patients reported involuntary loss of faeces at least once
per month, regardless of their diagnosis. Even if all nonresponders
would be classified as continent, which seems implausible, still 35%
of the population would report symptoms of faecal incontinence.
Other key findings were that active perianal disease was frequently
reported amongst the CD (39%) population, and that regular epi-
sodes of faecal incontinence were more common in patients with
active perianal disease. Furthermore, faecal incontinence and active
perianal disease were affecting quality of life on all 36-Item Short
Form Survey subscales, and active perianal disease (corrected in a
multivariate regression analysis) had a negative effect on employ-
ment status.
Community-based numbers of faecal incontinence in IBD
patients have sparsely been described; in one study, a prevalence
of faecal incontinence up to 74%, was reported, based on a
questionnaire with a response rate of only 33%.10 The authors
estimated a prevalence of 24% if all nonrespondents were classi-
fied as continent. In a tertiary population, faecal incontinence may
be more prevalent, as these patients may have more a complicated
disease course which potentially increases the risk of faecal incon-
tinence. A prevalence of 28% in 108 consecutive IBD patients of
a tertiary CD out-patient clinic has indeed been reported.7
Twenty-six per cent of a referral out-patient population in South
Asia reported complaints of faecal incontinence, in a study in
which patients with previous traumatic anal injury, concomitant
neurological disorders or psychiatric illnesses were excluded.8 In a
previous study, we reported a prevalence of 20% in a complex CD
population,9 using the same definition as in this study. These find-
ings imply that the prevalence in this study may be overestimated
(albeit still worrisome), which might be explained by a more than
average engaged population consisting of self-selected patients
being member of a patient organisation, whom already signed up
for surveys. Nevertheless, physicians need to be pro-active in
TABLE 2 Prevalence of faecal incontinence (≥ monthly) and associated quality of life. Patients with a stoma were excluded in this analysis
Variable Crohn’s disease Ulcerative Colitis
IBD not classifiable
by patient P-value
Stoma
No 529 (85%) 403 (95%) 46 (94%) <0.0001*
Female 397 (75%) 251 (62%) 27 (59%)
Male 132 (25%) 152 (38%) 19 (41%)
Yes 92 (15%) 19 (5%) 3 (6%)
Faecal incontinence
Number of patients 306 (58%) 225 (56%) 24 (52%) 0.60
Female 242 (79%) 162 (72%) 13 (54%)
Vaginal delivery 129 (53%) 97 (60%) 8 (62%)
Male 64 (21%) 63 (28%) 11 (46%)
Liquid stool
≥ monthly, < weekly 161 (53%) 196 (87%) 21 (88%)
≥ weekly 40 (13%) 22 (10%) 2 (8%)
Solid stool
≥ monthly, < weekly 102 (33%) 83 (37%) 10 (42%)
≥ weekly 9 (1%) 9 (4%) 1 (4%)
St. Marks incontinence score (mean, IQR) 9 (7-12) 9 (7-11) 7 (5-8) 0.011**
Related to:
Flare 130 (42%) 125 (56%) 10 (42%) 0.005*
Remission 125 (41%) 78 (35%) 9 (38%) 0.40
Nutrition 71 (23%) 47 (21%) 1 (4%) 0.09
Perianal surgery 15 (23%) 1 (8%) 0
Faecal incontinence quality of life (mean, IQR)
Lifestyle 3.0 (2.4-3.7) 2.9 (2.3-3.5) 2.8 (2.2-3.5) 0.16
Coping/behaviour 2.3 (1.7-2.8) 2.3 (1.8-2.8) 2.3 (1.7-2.9) 0.68
Depression/self-perception 2.8 (2.3-3.3) 3.0 (2.6-3.4) 2.8 (2.3-3.2) 0.30
Embarrassment 2.8 (2.3-3.3) 3.0 (2.3-3.3) 2.8 (2.3-3.3) 0.14
*Differences between Crohn’s disease and ulcerative colitis remained significant after Bonferroni correction (P < 0.017).
**Differences between Crohn’s disease and IBD-unknown remained significant after Bonferroni correction (P < 0.017).
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questioning IBD patients for symptoms of faecal incontinence, as
this distressing complaint is reported by a substantial proportion of
patients.
Remarkably, faecal incontinence was reported during periods of
both flare-ups as well as in remission. In addition, up to one-third of
the incontinent patients reported involuntary loss of solid stool, cor-
roborating that faecal incontinence not only occurs during periods of
active disease which has not been reported previously in the IBD
population. In patients with active disease, diarrhoea and proctitis
can be considered as contributing factors to faecal incontinence. In
remission, previously performed bowel resections, perianal fistula
surgery, and also rectal fibrosis associated with a decreased rectal
compliance are associated with an increased risk.9,10 Besides these
disease specific factors, other frequently related causes of faecal
incontinence (traumatic delivery, pudendal neuropathy, neurological
diseases) may also be responsible for the complaints. If active dis-
ease has been excluded, treatment can be started with fibre supple-
ments and physiotherapy  biofeedback. In patients in whom
conservative management has failed, additional anorectal physiology
testing (eg, anorectal manometry, rectal sensation/compliance tests,
endoanal ultrasonography and defaecography) might be consid-
ered,25 and a multidisciplinary approach with gastroenterologists,
gynaecologists and colorectal surgeons can be worthwhile to deter-
mine the best treatment strategy.
Perianal disease (fistulas in particular) remains a challenging prob-
lem in patients with CD. Since the advent of the tumour necrosis
factor antagonists, some improvement of fistula treatment has been
achieved. Results from the ACCENT II trial have shown that inflix-
imab is considered effective in up to 36% at a follow-up of
54 weeks,26 and adalimumab therapy was associated with increases
in fistula closure over time in the open label-extension study of the
CHARM.27 Another recent treatment option is mesenchymal stem
cell therapy, which, at week 52, appeared to be beneficial in (not
too) complex perianal fistulas in approximately 56% of CD patients
as compared to 39% success in controls, who were only operated
upon.28 In this patient group, potentially surgical treatment may
remain an alternative, but likewise often an unsuccessful therapeuti-
cal option. Fissures that are resistant to conservative treatment may
also require surgery, such as lateral internal sphincterotomy, which
in itself may induce faecal incontinence, particularly in women.29 In
addition, the association between anal stenosis and faecal inconti-
nence has been described previously.30
We have shown that patients with perianal disease more fre-
quently reported symptoms of faecal incontinence, which emphasises
the demand for development of new nonsurgical treatment options, as
perianal surgery in this group is discouraged. Furthermore, patients
with active perianal disease reported a diminished quality of life and a
higher rate of work disability as a result of their disease. This implied
that perianal disease may cause an economic burden.2,31 It needs to
be taken into account that more aggressive luminal disease, especially
in the colon or rectum, may also play a role in this, as it is related to
perianal disease.12 To assess the exact impact of perianal disease on
healthcare costs, a health-economics analysis will be needed, as previ-
ously performed by the COIN study group.1
We acknowledge that there were methodological limitations to
conducting this study. First, the survey was sent to a panel of self-
selected CCUVN patients. As approximately 80 000 people in the
Netherlands suffer from IBD, one of eight is member of the patient
association. The panel consisted of patients who signed up voluntary
to complete disease-related questionnaires. Hence, the group may be
represented by patients who are more dedicated to report their com-
plaints or have more severe disease. This potential bias always needs
to be considered when health-related outcomes are interpreted. Sec-
ond, the patients were asked to report their disease characteristics
themselves and no additional clinical (or endoscopic) information was
used to confirm the diagnosis, previously performed disease-related
interventions or current disease activity. Third, we acknowledge the
limitations of the perianal disease activity index to assess the preva-
lence of active perianal disease. From our perspective, this tool is
appropriate to indicate whether perianal disease is currently active or
not. However, the questionnaire cannot be used to estimate the preva-
lence of the different types of perianal disease (fissures/fistula), as
scores for different types are added up to the same category. Fourthly,
we used an online questionnaire to address the research questions,
although it has been demonstrated that Internet-respondents gener-
ally report a poorer quality of life than patients recruited from clinic.32
Bearing in mind the limitations, we were still able to show the
impact of faecal incontinence and perianal disease on quality of life.
Assessment of these conditions among the community based popu-
lation using patient reported outcome according to the terminology
of the US Food & Drug Administration has barely been performed
to date. To assess the specific effect of these embarrassing
TABLE 3 Quality of life in patients with symptoms of faecal
incontinence (≥ monthly) compared to those without
Variable Incontinent Continent P-value
SF-36 (mean, IQR)
Physical functioning 75 (65-95) 84 (75-100) <0.0001
Limitations due to
physical health
49 (0-100) 63 (25-100) <0.0001
Limitations due to
emotional problems
49 (0-100) 64 (33-100) <0.0001
Energy/fatigue 47 (30-65) 53 (35-75) <0.0001
Emotional well-being 71 (60-84) 74 (64-88) 0.005
Social functioning 63 (50-75) 73 (63-100) <0.0001
Pain 66 (45-80) 75 (68-90) <0.0001
General health 41 (25-55) 48 (30-65) <0.0001
Number of
patients ≤ 65 years
483 (87%) 379 (90%)
Job description
No job 121 (25%) 67 (18%)
0.002*
Paid job 312 (65%) 282 (74%)
Voluntary work 50 (10%) 30 (8%)
*Differences between patients with (65%) and without symptoms of fae-
cal continence (74%) with a paid job remained significant after Bonfer-
roni correction (P < 0.017).
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complaints, the use of patient reported outcome is essential, as the
status of a patient’s health condition is reported without amendment
or interpretation by a clinician or by anyone else. As such, this
methodology might provide more accurate results on the burden
compared to results collected by physicians only.
In conclusion, faecal incontinence and perianal disease are fre-
quently occurring in IBD patients, leading to an unmet need in terms
of therapeutic options. Awareness amongst physicians is needed to
ask actively for complaints of faecal incontinence, and development
of new therapies needs to be focussed on treatment of perianal dis-
ease, taking patient reported outcomes into account when describing
its efficacy.
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TABLE 4 Quality of life and symptoms of faecal incontinence (≥
monthly) in all patients with and without perianal disease. Patients
with a functioning stoma were excluded in continence related
analyses
Variable
Perianal
disease
Non-perianal
disease P-value
Number of patients 323 (30%) 769 (70%)
Crohn’s disease 244 (39%) 377 (61%)
Ulcerative colitis 69 (16%) 353 (84%)
IBD not classifiable
by patient
10 (20%) 39 (80%)
Quality of life
SF-36 (mean, IQR)
Physical functioning 74 (60-80) 80 (70-95) <0.0001
Limitations due to
physical health
47 (0-100) 57 (0-100) 0.001
Limitations due to
emotional problems
47 (0-100) 57 (0-100) 0.0002
Energy/fatigue 44 (25-60) 52 (35-70) <0.0001
Emotional well-being 69 (56-84) 73 (64-88) 0.001
Social functioning 60 (50-75) 69 (50-88) <0.0001
Pain 62 (45-78) 72 (58-90) <0.0001
General health 39 (25-55) 45 (30-60) <0.0001
Number of
patients ≤ 65 years
300 (93%) 678 (88%)
Job description 0.004*
No job 84 (28%) 146 (22%)
Paid job 183 (61%) 465 (69%)
Voluntary work 33 (11%) 68 (10%)
Result of their IBD 102 (34%) 144 (21%) <0.0001
Sick leave during
the past 6 months
87 (48%) 166 (36%) 0.007
Effect of IBD on
productivity at
work (Likert 0-10)
4.6 (2-7) 3.9 (1-7) 0.01
Number of patients
without a stoma
273 (85%) 705 (92%)
Faecal incontinence
Number of patients 182 (67%) 373 (53%) 0.003
Liquid stool
≥ monthly,
< weekly
152 (84%) 326 (88%)
≥ weekly 28 (15%) 36 (10%)
Solid stool
≥ monthly,
< weekly
64 (35%) 130 (35%)
≥ weekly 8 (4%) 12 (3%)
SMIS (mean, IQR) 10 (7-12) 9 (7-11) 0.18
Faecal incontinence quality of life
Lifestyle 2.8 (2.2-3.5) 3.0 (2.5-3.6) 0.04
Coping/behaviour 2.1 (1.6-2.5) 2.4 (1.9-2.9) 0.04
(Continues)
TABLE 4 (Continued)
Variable
Perianal
disease
Non-perianal
disease P-value
Depression
/self-perception
2.7 (2.2-3.1) 3.0 (2.6-3.4) 0.03
Embarrassment 2.7 (2.3-3.3) 3.0 (2.3-3.3) 0.04
*Differences between patients with (61%) and without perianal disease (69%)
with a paid job remained significant after Bonferroni correction (P < 0.017).
TABLE 5 Univariate and multivariate binary regression analysis of
variables and its associations with employment (no paid job = 0 vs
paid job = 1)
Variable
Univariate Multivariate
Odds Ratio
(95% CI) P-value
Odds Ratio
(95% CI) P-value
Stoma
No Reference — Reference —
Yes 0.63 (0.41-0.95) 0.03 0.68 (0.44-1.03) 0.07
Active perianal disease
No Reference — Reference —
Yes 0.66 (0.50-0.88) 0.004 0.71 (0.53-0.95) 0.02
Faecal incontinence
No Reference — Reference —
Yes 0.65 (0.49-0.86) 0.002 0.68 (0.51-0.90) 0.007
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